* Parkinson's drug hope fails in major trial
* Phytopharm's shares fall more than 80 pct (Adds details, analyst reaction, shares)
LONDON, Feb 18 (Reuters) - Phytopharm said its major drug hope for treating Parkinson's disease had failed in a clinical trial, the latest British biotech company to disappoint after showing early promise.
Shares in Phytopharm fell more than 80 percent on Monday after it said its drug, Cogane, showed no benefit over placebo in the treatment of more than 400 patients with early-stage Parkinson's, a neurodegenerative disease.
Chief Executive Tim Sharpington said he was disappointed.
"Cogane had demonstrated encouraging efficacy in a wide range of industry standard pre-clinical models but this promise has not translated into clinically meaningful efficacy," he said.
Phytopharm hoped its compounds had the potential to be a new class of therapy for neurodegenerative diseases, motor neuron disease and glaucoma.
Cogane had demonstrated neuroprotective effects in preclinical models, the company had said, with indications that it could ease the symptoms and slow the progression of Parkinson's, a condition where part of the brain becomes more damaged over time.
Phytopharm said on Monday it had halted all research and development spending while it reviewed its drugs pipeline.
Its shares were trading down 82.25 percent by 0914 GMT, giving it a market value of just over 6 million pounds.
Analyst Paul Cuddon at Peel Hunt said the result was a conclusive failure for Phytopharm's key asset, and he attributed no value to the group's remaining pipeline of drugs.
"The comprehensive nature of the failure raises questions over the relevance of the pre-clinical models used, and the size/expense of the trial that was required to prove that Cogane was futile," he said.
"Ultimately this outcome should have been reached at a lesser loss for shareholders."
He said Phytopharm was likely to join the ranks of Renovo , Minster and Antisoma, of all which saw promising drugs fail in later-stage clinical trials.
"Until companies are better able to select for specific genetically defined patients for targeted drugs, UK pre-revenue drug development companies will remain a lottery," Cuddon said.
(Reporting by Paul Sandle; Editing by Erica Billingham)